A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Merck (MSD)
410 trials monitored
See 27 trials at risk
Ovarian Cancer
1,341 trials monitored
See 94 trials at risk
Endometrial Cancer
696 trials monitored
See 49 trials at risk
Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment. MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people. The goals of this trial are to learn about: * The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems. * What happens to different dose levels (amounts) of MK-6255 in the body over time.
Trial Details
NCT Number NCT07870278
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Ovarian Neoplasms, Endometrial Neoplasms
Related terms Endometrial Neoplasms, Ovarian Neoplasms
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov